Panmure Gordon Reaffirms “Hold” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reissued by Panmure Gordon in a research note issued on Friday. They currently have a GBX 4,400 ($73.55) target price on the stock. Panmure Gordon’s price objective indicates a potential downside of 0.26% from the stock’s previous close.
AstraZeneca plc (LON:AZN) opened at 4438.50 on Friday. AstraZeneca plc has a 1-year low of GBX 3086.50 and a 1-year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4313.00 and a 200-day moving average of GBX 4208.. The company’s market cap is £56.058 billion.
AZN has been the subject of a number of other recent research reports. Analysts at Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday. They now have a GBX 4,000 ($66.87) price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 4,500 ($75.23) price target on the stock. Six research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 4,055.48 ($67.79).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.